Clinical trials: Overweight and/or Obesity
Diabetes Mellitus, Type 2
REASSURE: The Effect of Rimonabant on HbA1c in Overweight or Obese Patients With Type 2 Diabetes Not Adequately Controlled on 2 Oral Antidiabetic Agents
Primary: To assess the effects of rimonabant on HbA1c in patients with Type 2 diabetes who are overweight or obese (Body Mass Index (BMI) > 27 kg/m² and BMI < 40 kg/m²), have uncontrolled HbA1c (7.0% - 9.0% inclusive) and are…
- Trial name
- REASSURE (NCT00546325)
- Testing
- Rimonabant
- Where
- Australia
- Volunteers
- 358 people
- Sponsor
- Sanofi
Obesity, Overweight
A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight
The purpose of this study is to evaluate how well Eloralintide (LY3841136) is tolerated and what side effects may occur in overweight and obese Chinese participants.
- Trial name
- NCT06916091
- Testing
- Eloralintide
- Where
- Singapore
- Volunteers
- 30 people
- Sponsor
- Eli Lilly and Company
Obesity, Overweight
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
Study ASC30-302 (AURORA-2) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral…
- Conditions
- Obesity, Overweight, Chronic Weight Management, Type 2 Diabetes Mellitus
- Trial name
- AURORA-2 (NCT07743450)
- Testing
- ASC30 tablets A1
- Where
- 135 sites in United States, Czechia and 4 more
- Volunteers
- 1,560 people
- Sponsor
- Ascletis Pharma (China) Co., Limited
Weight Management
A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity
The aim of the study is to evaluate the efficacy and safety of XW003 versus placebo in adults with overweight or obesity
- Trial name
- NCT05813795
- Testing
- Ecnoglutide Low Dosage, Ecnoglutide Medium Dosage, Ecnoglutide High Dosage
- Where
- China
- Volunteers
- 664 people
- Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
Type 2 Diabetes Mellitus, Obese
Safety, Tolerability, and Efficacy of ISIS-PTP1BRx in Type 2 Diabetes
The purpose of this study is to evaluate the safety, tolerability, and efficacy of ISIS-PTP1BRx + oral antidiabetic drug/s (metformin and/or sulfonylurea) versus placebo + oral antidiabetic drug/s.
- Trial name
- NCT01918865
- Testing
- ISIS-PTP1BRx, daily OAD (metformin and/or sulfonylurea)
- Where
- 21 sites in Argentina, Canada and 1 more
- Volunteers
- 92 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Overweight , Obesity
Phase 2 Clinical Study of MWN105 Injection in Participants With Overweight or Obesity
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the pharmacokinetic characteristics, efficacy, and safety of MWN105 Injection in non-diabetic participants with overweight or obesity.
- Trial name
- NCT07804810
- Testing
- MWN105 1, MWN105 2, MWN105 3
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Obesity and Type 2 Diabetes
BMS-646256 in Obese and Overweight Type 2 Diabetics
This is a placebo-controlled, randomized, double-blind, parallel arm, multicenter, dose-ranging phase IIb trial to assess glycemic and weight loss efficacy and safety of BMS-646256 in overweight and obese patients with type 2…
- Trial name
- NCT00541567
- Testing
- ibipinabant
- Volunteers
- 600 people
- Sponsor
- Solvay Pharmaceuticals
Adolescents With Obesity or Overweight With Weight-Related Comorbidities
A Study of IBI362 in Chinese Adolescents With Obesity or Overweight
The study is designed to assess the efficacy and safety of multiple doses of IBI362 in Chinese adolescent subjects with obesity or overweight.
- Trial name
- NCT07255209
- Testing
- IBI362
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Obesity
A Study of RGT001-075 in Participants With Obesity or Overweight With Weight-Related Comorbidities
The main purpose of this study was to evaluate the safety and tolerability of RGT001-075 in healthy participants with obesity
- Trial name
- NCT06277934
- Testing
- RGT001-075
- Where
- 10 sites in United States
- Volunteers
- 73 people
- Sponsor
- Regor Pharmaceuticals Inc.
Overweight, Obesity
A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or Obesity
This study tests how well different doses of the medicine NNC0662-0419 help people living with overweight or obesity. The purpose of the study is to find out if NNC0662-0419 is safe and effective for treating people living with…
- Trial name
- NCT07184632
- Testing
- NNC0662-0419
- Where
- 2 sites in United States
- Volunteers
- 224 people
- Sponsor
- Novo Nordisk A/S
Obstructive Sleep Apnea
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy
This Phase 3 clinical trial is designed to evaluate the efficacy and safety of maridebart cafraglutide compared to placebo over a 52-week period in adults with obstructive sleep apnea (OSA) who are not on PAP therapy and are…
- Trial name
- MARITIME-OSA-2 (NCT07226765)
- Testing
- Maridebart cafraglutide
- Where
- 57 sites in United States, Australia and 9 more
- Volunteers
- 250 people
- Sponsor
- Amgen
Chronic Kidney Disease
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
The study evaluates the safety of different doses of a new medicine called NNC0519 0130. It also looks into how the medicine may improve kidney function in participants with chronic kidney disease with or without type 2 diabetes…
- Trial name
- NCT06717698
- Testing
- NNC0519-0130, Semaglutide
- Where
- 147 sites in United States, Argentina and 12 more
- Volunteers
- 465 people
- Sponsor
- Novo Nordisk A/S
Obesity or Overweight
A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity
This study will evaluate the efficacy and safety of petrelintide compared with placebo, in conjunction with a reduced-calorie diet and increased physical activity, for weight management in participants living with overweight or…
- Trial name
- ZUPREME-3 (NCT07843498)
- Testing
- Petrelintide
- Where
- 3 sites in United States
- Volunteers
- 3,900 people
- Sponsor
- Hoffmann-La Roche
Healthy
A Study in Women With Overweight or Obesity to Test Whether Different Doses of BI 456906 Influence the Amount of a Contraceptive in the Blood
This study is open to women with overweight or obesity who are otherwise healthy. Women with a body mass index (BMI) from 27 to 40 kg/m2 can participate.
- Trial name
- NCT05896384
- Testing
- BI 456906, Microgynon®
- Where
- Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Overweight or Obesity
A Proof of Concept Trial in Overweight and Obese Patients, Investigating Effect of EMP16-02 on Body Weight (Primary)
This study is a proof of concept study to demonstrate that EMP16-02, a fixed dose combination (FDC) of orlistat and acarbose in an oral multiple-unit modified release (MR) formulation leads to a clinically relevant decrease in…
- Trial name
- NCT04521751
- Testing
- EMP16-02 120 mg orlistat/40 mg acarbose, EMP16-02 150 mg orlistat/50 mg acarbose
- Where
- 2 sites in Sweden
- Volunteers
- 156 people
- Sponsor
- Empros Pharma AB
Obesity, Morbid
Early Feasibility Study: Assessment of Self-Forming Magnetic Anastomosis Device and Delivery System (SFM) in Obese Patients, When Used to Create a Duodenal-Ileal Anastomosis Post SG (SNAP-PS), or Used to Create a Jejuno-Jejunal (J-J) Anastomosis
The objectives of this study are to assess the initial safety and device functionality of the SFM Anastomosis System including delivery systems when used to create a duodenal-ileal (D-I) anastomosis with patients with prior…
- Trial name
- GIW-J-J (NCT06200896)
- Testing
- Self Forming Magnets used to Create A Compression Anastomosis
- Where
- Chile
- Volunteers
- 28 people
- Sponsor
- GI Windows, Inc.
Obesity, Aging
Variability of Physical Assessments in an Older Population That is Overweight or Obese
Variability of physical assessments in an older population that is overweight or obese.
- Trial name
- NCT05174923
- Testing
- Short Performance Physical Battery (SPPB Test), 30 Second Chair Stand Test (30CST), Hand grip dynamometry
- Where
- 2 sites in United States
- Volunteers
- 58 people
- Sponsor
- Versanis Bio, Inc.
Overweight and Obesity
Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity
Novo Nordisk are doing this study to see if semaglutide tablets can be used as a treatment to help people living with overweight or obesity lose weight. This study will look at the change in participants' body weight.
- Trial name
- OASIS 2 (NCT05132088)
- Testing
- semaglutide 50 mg
- Where
- 15 sites in Japan, South Korea
- Volunteers
- 201 people
- Sponsor
- Novo Nordisk A/S
Obesity
A Research Study on How NNC0487-0111 Works in People With Overweight or Obesity
NNC0487-0111 is a new medicine similar to 2 hormones that are produced in human body: amylin and glucagon-like peptide-1 (GLP-1). Both hormones work like body's own hormones and help the body to feel full.
- Trial name
- NCT05369390
- Testing
- NNC0487-0111 A, NNC0487-0111 B
- Where
- 2 sites in United States
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Obesity
A Study to Test How Well Different Doses of BI 1356225 Are Tolerated by Men and Women With Obesity or Overweight
The primary objective of this trial is to investigate safety and tolerability of BI 1356225 in male and female patients with overweight and obesity following oral administration of multiple rising doses per day over 28 days.
- Trial name
- NCT04447261
- Testing
- BI 1356225
- Where
- Germany
- Volunteers
- 87 people
- Sponsor
- Boehringer Ingelheim